Niranjan Sudhakar

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics · 2021 · 167 citations · Full text

Medicine, Immunology, Oncology +17

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

David M. Briere, Niranjan Sudhakar, David Woods et al. · Cancer Immunology Immunotherapy · 2017 · 145 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 108 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15